REDWOOD CITY, Calif.,
Feb. 22, 2019 /PRNewswire/ -- AcelRx
Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical
company, today announced that it will release fourth quarter and
annual financial results after market close on Thursday, March 7th, 2019. AcelRx management will
host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on March 7, 2019 to discuss the financial results
and provide a corporate update.
Investors who wish to participate in the conference call may do
so by dialing (866) 361-2335 for domestic callers, (855) 669-9657
for Canadian callers or (412) 902-4204 for international callers.
Those interested in listening to the conference call live via the
Internet may do so by visiting the Investors page of the company's
website at www.acelrx.com and clicking on the webcast link on the
Investors home page.
A webcast replay will be available on the AcelRx website for 90
days following the call by visiting the Investor page of the
company's website at www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company
focused on the development and commercialization of innovative
therapies for use in medically supervised settings. AcelRx's
proprietary, non-invasive sublingual formulation technology
delivers sufentanil with consistent pharmacokinetic profiles. The
Company has one approved product in the U.S., DSUVIA (sufentanil
sublingual tablet, 30 mcg), known as DZUVEO in Europe, indicated for the management of acute
pain severe enough to require an opioid analgesic for adult
patients in certified medically supervised healthcare settings, and
one product candidate, Zalviso®(sufentanil sublingual tablet
system, SST system, 15 mcg) being developed as an innovatively
designed patient-controlled analgesia (PCA) system for reduction of
moderate-to-severe acute pain in medically supervised settings.
DZUVEO and Zalviso are both approved products in Europe. Zalviso is not approved in the U.S.
For additional information about AcelRx, please visit
www.acelrx.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/acelrx-to-announce-fourth-quarter-2018-results-and-provide-a-corporate-update-on-thursday-march-7th-2019-300800352.html
SOURCE AcelRx Pharmaceuticals, Inc.